Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermedi...
Foxconn Q1 revenue jumps 29.7% on AI demand
FUSHILAI released its performance for the first three quarters, with a net profit attributable to the parent company of 73.3966 million yuan, an increase of 430.16%
FUSHILAI: Cumulatively repurchased 950,000 shares
FUSHILAI: The total number of shares repurchased by the company is 400,000 shares
Pharmaceutical stocks continue to be strong, FUSHILAI hits the 20% limit up, Tuoxin Pharmaceutical and Cosunter rise over 10%, Xizang Weixinkang Pharmaceutical, MEDISAN and several other stocks hit the limit up
FUSHILAI plans to spend between 20 million and 40 million yuan to implement a buyback